
NASDAQHealthcareBiotechnology
أحدث البيانات المتاحة
3.72 US$
−0.05 US$ · -1.33%
Taysha Gene Therapies, Inc. is a biotech firm specializing in the creation and market introduction of gene therapies that utilize adeno-associated virus (AAV) vectors. Its core mission is to tackle inherited diseases affecting the central nervous system (CNS). The company's development pipeline features several key programs: TSHA-120 is aimed at giant axonal neuropathy; TSHA-102 is in development for Rett syndrome; TSHA-121 and TSHA-118 are both being advanced for CLN1 disease; TSHA-105 addresses SLC13A5 Deficiency; and TSHA-101 targets GM2 gangliosidosis. Furthermore, Taysha has forged a strategic alliance with The University of Texas Southwestern Medical Center to jointly advance and bring to market innovative gene therapy solutions. Founded in 2019, the company operates from its headquarters in Dallas, Texas.
الإغلاق السابق
3.72 US$
−0.05 US$ · -1.33%
تستخدم الأوقات اليومية المنطقة الزمنية ET. قد تتأخر بيانات السوق.
Taysha Gene Therapies, Inc. is a biotech firm specializing in the creation and market introduction of gene therapies that utilize adeno-associated virus (AAV) vectors. Its core mission is to tackle inherited diseases affecting the central nervous system (CNS). The company's development pipeline features several key programs: TSHA-120 is aimed at giant axonal neuropathy; TSHA-102 is in development for Rett syndrome; TSHA-121 and TSHA-118 are both being advanced for CLN1 disease; TSHA-105 addresses SLC13A5 Deficiency; and TSHA-101 targets GM2 gangliosidosis. Furthermore, Taysha has forged a strategic alliance with The University of Texas Southwestern Medical Center to jointly advance and bring to market innovative gene therapy solutions. Founded in 2019, the company operates from its headquarters in Dallas, Texas.
نطاق اليوم
السعر الحالي 3.72 US$
نطاق 52 أسبوعًا
السعر الحالي 3.72 US$
تستخدم الأوقات اليومية المنطقة الزمنية ET. قد تتأخر بيانات السوق.
نقاط GoAI
احتفاظ
تقييم
53
قيمة عادلة
المشاعر
69
صعودي
المخاطر
48
مخاطر أعلى من المعتاد
الزخم
61
زخم متزايد
بحث كامل عن GoAI
تابع للاطلاع على أدلة ومحفزات ومخاطر أعمق.
Taysha Gene Therapies, Inc. is a biotech firm specializing in the creation and market introduction of gene therapies that utilize adeno-associated virus (AAV) vectors. Its core mission is to tackle inherited diseases affecting the central nervous system (CNS). The company's development pipeline features several key programs: TSHA-120 is aimed at giant axonal neuropathy; TSHA-102 is in development for Rett syndrome; TSHA-121 and TSHA-118 are both being advanced for CLN1 disease; TSHA-105 addresses SLC13A5 Deficiency; and TSHA-101 targets GM2 gangliosidosis. Furthermore, Taysha has forged a strategic alliance with The University of Texas Southwestern Medical Center to jointly advance and bring to market innovative gene therapy solutions. Founded in 2019, the company operates from its headquarters in Dallas, Texas.
نطاق اليوم
السعر الحالي 3.72 US$
نطاق 52 أسبوعًا
السعر الحالي 3.72 US$
أحدث النتائج المعلنة
أحدث النتائج المعلنة
قد تتغير تقديرات المحللين الخارجيين، وهي ليست توصيات من GoAI.
متوسط الهدف
14.00 US$
ارتفاع محتمل بنسبة 276.34%صناديق متداولة تفصح عن تعرضها لهذا السهم.
Vanguard Morningstar Total Stock Market ETFVTI29.91 مليون0.00%689.3 مليار USD0.03%340.02 US$-3.52%
iShares Russell 2000 ETFIWM26.55 مليون0.04%71.54 مليار USD0.19%256.61 US$-2.88%
State Street SPDR S&P Biotech ETFXBI19.86 مليون0.21%9.64 مليار USD0.35%140.18 US$-2.73%
Vanguard Extended Market ETFVXF12.75 مليون0.01%30.2 مليار USD0.05%211.44 US$-3.21%
iShares Russell 2000 Growth ETFIWO9.45 مليون0.07%12.73 مليار USD0.24%320.43 US$-3.57%
iShares Biotechnology ETFIBB7.62 مليون0.07%10.53 مليار USD0.44%199.54 US$-2.05%
Vanguard Russell 2000 ETFVTWO6.48 مليون0.04%16.8 مليار USD0.06%103.76 US$-2.76%
Schwab U.S. Small-Cap ETFSCHA5.36 مليون0.03%20.45 مليار USD0.03%30.51 US$-2.83%
Vanguard Morningstar Total Stock Market ETFVTI
iShares Russell 2000 ETFIWM
State Street SPDR S&P Biotech ETFXBI
Vanguard Extended Market ETFVXF
iShares Russell 2000 Growth ETFIWO
iShares Biotechnology ETFIBB
Vanguard Russell 2000 ETFVTWO
Schwab U.S. Small-Cap ETFSCHAالمحتوى المُنشأ بالذكاء الاصطناعي وبيانات السوق المتأخرة لأغراض معلوماتية وتعليمية فقط، ولا تُعد نصيحة استثمارية.